MedTrace Logo

Comparative Bioavailability Study of Human Chorionic Gonadotropin (hCG)-IBSA Versus a Marketed hCG Formulation

NCT03735030 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2021-03-11

No results posted yet for this study

Summary

In the present study, the rate and extent of hCG absorption will be compared between the two treatments in healthy women aged 20 to 45 years.

Conditions

Interventions

DRUG

Human hCG 10'000 IU

A single dose of 10'000 IU of human hCG will be injected in 24 healthy subject volunteers.

DRUG

Recombinant hCG 6'500 IU

A single dose of 6'500 IU recombinant hCG will be injected in 24 healthy subject volunteers.

Sponsors & Collaborators

  • IBSA Institut Biochimique SA

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-27
Primary Completion
2019-08-02
Completion
2019-08-02

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03735030 on ClinicalTrials.gov